Yun-Hua Yue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yun-Hua Yue has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Jie Xue
Department of Neurology, Yangpu Hospital Tongji University School of Medicine, Shanghai, China
12 shared publicationsDong Zhang
Department of Neurology, Yangpu Hospital, School of Medicine, Tongji University
11 shared publicationsXiao-Guang Zhang
Department of Neurology, Yangpu Hospital Tongji University School of Medicine, Shanghai, China
9 shared publicationsYing Ding
Department of Neurology, Yangpu Hospital, School of Medicine Tongji University Shanghai China
7 shared publicationsLiang Hu
Department of Neurology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China
6 shared publicationsZhizhang Li
Department of Neurology, Yangpu Hospital, School of Medicine Tongji University Shanghai China
6 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1823868
Imaging patterns of hemorrhagic transformation after tenecteplase versus alteplase in real-world practice
Background: While randomized trials have demonstrated noninferiority of tenecteplase compared with alteplase in terms of functional outcomes and symptomatic intracranial hemorrhage (sICH), differences in hemorrhagic imaging phenotypes remain insufficiently explored in real-world practice. Methods: We conducted a retrospective real-world cohort study of consecutive patients with acute ischemic stroke treated with intravenous thrombolysis between January and December 2025. The primary endpoint was ordinal shift in hemorrhagic transformation severity according to the Heidelberg Bleeding Classification (HBC). Secondary endpoints included sICH. Multivariable logistic regression was performed to identify independent predictors of hemorrhage. Results: A total of 95 patients were included (alteplase n = 41; tenecteplase n = 54). Baseline characteristics were largely comparable between groups. No significant difference in sICH incidence was observed. Although remote hemorrhagic phenotypes were numerically more frequent in the tenecteplase group, no significant ordinal shift was detected between treatment groups. In multivariable analysis, higher baseline NIHSS score (OR 1.10, 95% CI 1.02–1.18, p = 0.013) and longer ONT (OR 1.12 per 10 min, 95% CI 1.02–1.23, p = 0.016) were independently associated with intracranial hemorrhage, whereas thrombolytic agent type was not. Conclusion: In this small exploratory real-world cohort, tenecteplase was not associated with an obvious increase in hemorrhagic events compared with alteplase. However, because of the limited sample size and small number of severe hemorrhagic events, these findings should be interpreted as preliminary and hypothesis-generating. Imaging-based classification using the Heidelberg framework did not reveal a significant shift toward more severe hemorrhagic phenotypes.
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1823868
Open AccessImaging patterns of hemorrhagic transformation after tenecteplase versus alteplase in real-world practice
Background: While randomized trials have demonstrated noninferiority of tenecteplase compared with alteplase in terms of functional outcomes and symptomatic intracranial hemorrhage (sICH), differences in hemorrhagic imaging phenotypes remain insufficiently explored in real-world practice. Methods: We conducted a retrospective real-world cohort study of consecutive patients with acute ischemic stroke treated with intravenous thrombolysis between January and December 2025. The primary endpoint was ordinal shift in hemorrhagic transformation severity according to the Heidelberg Bleeding Classification (HBC). Secondary endpoints included sICH. Multivariable logistic regression was performed to identify independent predictors of hemorrhage. Results: A total of 95 patients were included (alteplase n = 41; tenecteplase n = 54). Baseline characteristics were largely comparable between groups. No significant difference in sICH incidence was observed. Although remote hemorrhagic phenotypes were numerically more frequent in the tenecteplase group, no significant ordinal shift was detected between treatment groups. In multivariable analysis, higher baseline NIHSS score (OR 1.10, 95% CI 1.02–1.18, p = 0.013) and longer ONT (OR 1.12 per 10 min, 95% CI 1.02–1.23, p = 0.016) were independently associated with intracranial hemorrhage, whereas thrombolytic agent type was not. Conclusion: In this small exploratory real-world cohort, tenecteplase was not associated with an obvious increase in hemorrhagic events compared with alteplase. However, because of the limited sample size and small number of severe hemorrhagic events, these findings should be interpreted as preliminary and hypothesis-generating. Imaging-based classification using the Heidelberg framework did not reveal a significant shift toward more severe hemorrhagic phenotypes.
- Open Access
- 11 May 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (5) , e71484
Association of Admission Glucose‐to‐Lymphocyte Ratio With 90‐Day Functional Outcome in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis
Background: The glucose‐to‐lymphocyte ratio (GLR), a composite biomarker reflecting metabolic and immune‐inflammatory status, has shown prognostic value in several clinical settings. However, its relevance in patients with acute ischemic stroke (AIS) undergoing intravenous thrombolysis (IVT) remains unclear. We investigated the association between admission GLR and poor functional outcome at 90 days in this population. Methods: In this retrospective single‐center study, consecutive patients with AIS treated with IVT between May 2016 and December 2025 were included. The primary outcome was poor functional outcome at 90 days, defined as a modified Rankin Scale score of 3–6. GLR was analyzed as both a continuous and a categorical variable. Multivariable logistic regression, inverse probability weighting, restricted cubic spline analysis, subgroup analyses, and sensitivity analyses were performed after multiple imputation for missing data. Results: Among 785 patients, 29.64% had poor functional outcome at 90 days. The optimal GLR cutoff was 4.137, with a pooled AUC of 0.623 (95% CI 0.578–0.665). In the fully adjusted model, GLR was independently associated with poor outcome both as a continuous variable (OR = 1.071, 95% CI 1.004–1.144, p = 0.038) and as a categorical variable (OR = 1.639, 95% CI 1.057–2.543, p = 0.027). The findings remained robust in an alternative lipid‐adjusted model and IPW analyses. RCS analysis suggested an overall linear association, whereas sensitivity analyses using an alternative mRS dichotomization were not statistically significant. Conclusions: Elevated admission GLR was independently associated with an increased risk of poor functional outcome at 90 days in patients with AIS undergoing IVT. GLR may provide useful supplementary prognostic information for early risk stratification, although its standalone discriminatory performance was modest.
- 11 May 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (5) , e71484
Open AccessAssociation of Admission Glucose‐to‐Lymphocyte Ratio With 90‐Day Functional Outcome in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis
Background: The glucose‐to‐lymphocyte ratio (GLR), a composite biomarker reflecting metabolic and immune‐inflammatory status, has shown prognostic value in several clinical settings. However, its relevance in patients with acute ischemic stroke (AIS) undergoing intravenous thrombolysis (IVT) remains unclear. We investigated the association between admission GLR and poor functional outcome at 90 days in this population. Methods: In this retrospective single‐center study, consecutive patients with AIS treated with IVT between May 2016 and December 2025 were included. The primary outcome was poor functional outcome at 90 days, defined as a modified Rankin Scale score of 3–6. GLR was analyzed as both a continuous and a categorical variable. Multivariable logistic regression, inverse probability weighting, restricted cubic spline analysis, subgroup analyses, and sensitivity analyses were performed after multiple imputation for missing data. Results: Among 785 patients, 29.64% had poor functional outcome at 90 days. The optimal GLR cutoff was 4.137, with a pooled AUC of 0.623 (95% CI 0.578–0.665). In the fully adjusted model, GLR was independently associated with poor outcome both as a continuous variable (OR = 1.071, 95% CI 1.004–1.144, p = 0.038) and as a categorical variable (OR = 1.639, 95% CI 1.057–2.543, p = 0.027). The findings remained robust in an alternative lipid‐adjusted model and IPW analyses. RCS analysis suggested an overall linear association, whereas sensitivity analyses using an alternative mRS dichotomization were not statistically significant. Conclusions: Elevated admission GLR was independently associated with an increased risk of poor functional outcome at 90 days in patients with AIS undergoing IVT. GLR may provide useful supplementary prognostic information for early risk stratification, although its standalone discriminatory performance was modest.
- Open Access
- 30 April 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Incremental value of genetic polymorphisms in prognostic models for ischemic stroke
- 30 April 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessIncremental value of genetic polymorphisms in prognostic models for ischemic stroke
- Open Access
- 8 January 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Rare early-onset radiation-induced lumbosacral plexopathy in cervical cancer: a case report
Radiation-induced lumbosacral plexopathy (RILSP) is a rare and debilitating complication of pelvic radiotherapy, classically presenting months to decades a
- 8 January 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessRare early-onset radiation-induced lumbosacral plexopathy in cervical cancer: a case report
Radiation-induced lumbosacral plexopathy (RILSP) is a rare and debilitating complication of pelvic radiotherapy, classically presenting months to decades a
- Open Access
- 14 August 2025
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1581758
Transcriptomic features of immune inflammation and neural plasticity associated with early neurological improvement in acute ischemic stroke patients with large vessel occlusion
Background: Acute ischemic stroke (AIS) caused by large vessel occlusion (LVO) is a leading cause of disability and mortality worldwide. Although endovascular thrombectomy (EVT) has significantly improved outcomes, many patients do not achieve early neurological improvement (ENI) despite timely reperfusion. This study aims to investigate the peripheral blood mRNA molecular characteristics and underlying mechanisms associated with ENI after EVT in AIS-LVO patients, to inform individualized treatment and optimize prognosis.Methods: This retrospective study included AIS-LVO patients who underwent EVT between January 2022 and December 2023. Peripheral blood samples were collected before reperfusion therapy for mRNA transcriptome sequencing and bioinformatic analysis. Patients were grouped according to ENI status. Differentially expressed genes (DEGs) were identified, and functional enrichment, signaling pathway, and protein-protein interaction network analyses were performed.Results: A total of 108 patients were initially screened, and 20 were ultimately included in the study (13 in the ENI group and 7 in the non-ENI group). Among the 20,501 genes detected, 752 were found to be significantly differentially expressed, with 208 upregulated and 544 downregulated. The upregulated genes in the ENI group were mainly enriched in immune and inflammatory response pathways, such as NOD-like receptor and Toll-like receptor signaling. In contrast, the downregulated genes were primarily associated with neurodevelopment and synaptic plasticity. Protein-protein interaction analysis identified immune-related genes, including JUN, IL1A, and CCR5, as central nodes. Overall, the ENI group exhibited a dynamic balance between immune activation and suppression of neuronal plasticity.Conclusion: This study reveals the transcriptomic characteristics of ENI in AIS-LVO patients during the acute phase, highlighting the protective roles of moderate immune-inflammatory activation and suppression of neural plasticity in acute injury response. The identification of related molecular pathways and biomarkers provides a theoretical basis for individualized treatment and improved functional outcomes. Future studies should expand sample size and integrate single-cell sequencing and liquid biopsy multi-omics approaches to further clarify the molecular mechanisms of ENI and promote clinical translation.
- 14 August 2025
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1581758
Open AccessTranscriptomic features of immune inflammation and neural plasticity associated with early neurological improvement in acute ischemic stroke patients with large vessel occlusion
Background: Acute ischemic stroke (AIS) caused by large vessel occlusion (LVO) is a leading cause of disability and mortality worldwide. Although endovascular thrombectomy (EVT) has significantly improved outcomes, many patients do not achieve early neurological improvement (ENI) despite timely reperfusion. This study aims to investigate the peripheral blood mRNA molecular characteristics and underlying mechanisms associated with ENI after EVT in AIS-LVO patients, to inform individualized treatment and optimize prognosis.Methods: This retrospective study included AIS-LVO patients who underwent EVT between January 2022 and December 2023. Peripheral blood samples were collected before reperfusion therapy for mRNA transcriptome sequencing and bioinformatic analysis. Patients were grouped according to ENI status. Differentially expressed genes (DEGs) were identified, and functional enrichment, signaling pathway, and protein-protein interaction network analyses were performed.Results: A total of 108 patients were initially screened, and 20 were ultimately included in the study (13 in the ENI group and 7 in the non-ENI group). Among the 20,501 genes detected, 752 were found to be significantly differentially expressed, with 208 upregulated and 544 downregulated. The upregulated genes in the ENI group were mainly enriched in immune and inflammatory response pathways, such as NOD-like receptor and Toll-like receptor signaling. In contrast, the downregulated genes were primarily associated with neurodevelopment and synaptic plasticity. Protein-protein interaction analysis identified immune-related genes, including JUN, IL1A, and CCR5, as central nodes. Overall, the ENI group exhibited a dynamic balance between immune activation and suppression of neuronal plasticity.Conclusion: This study reveals the transcriptomic characteristics of ENI in AIS-LVO patients during the acute phase, highlighting the protective roles of moderate immune-inflammatory activation and suppression of neural plasticity in acute injury response. The identification of related molecular pathways and biomarkers provides a theoretical basis for individualized treatment and improved functional outcomes. Future studies should expand sample size and integrate single-cell sequencing and liquid biopsy multi-omics approaches to further clarify the molecular mechanisms of ENI and promote clinical translation.
- Open Access
- 5 June 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1581747
The glucose-to-potassium ratio: a predictor of poor functional outcomes in stroke patients receiving thrombolytic therapy
Background: The glucose-to-potassium ratio has shown promise as a biomarker in neurological disorders, but its prognostic value in acute ischemic stroke (AIS) after intravenous thrombolysis (IVT) continues to be uncertain. The study explores the relationship between admission GPR and 90-day functional outcomes in AIS patients undergoing IVT treatment.Methods: A retrospective analysis included 649 AIS patients undergoing IVT between May 2016 and December 2023. Baseline clinical, laboratory, and imaging data were analyzed. GPR was calculated from serum glucose and potassium levels at admission. A modified Rankin Scale score of 3 to 6 at 90 days was used to define poor functional outcomes. Logistic regression and restricted cubic splines assessed the GPR-outcome relationship, adjusting for confounders. Receiver operating characteristic (ROC) analysis evaluated GPR’s predictive value.Results: Among 649 patients, 174 (26.8%) had poor outcomes. Median GPR was significantly higher in these patients (2.14 vs. 1.88, p < 0.001). Higher GPR independently predicted negative consequences (OR, 1.821; 95% CI, 1.340–2.473, p < 0.001). Subgroup analysis indicated a stronger association in non-diabetic patients. ROC analysis demonstrated an area under the curve (AUC) of 0.631 (95% CI, 0.585–0.677, p < 0.001) for GPR in predicting poor functional outcomes.Conclusion: High GPR levels are independently linked to unfavorable 90-day functional outcomes in AIS patients who received IVT, suggesting its potential as a prognostic biomarker. Further studies are warranted to validate these findings.
- 5 June 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1581747
Open AccessThe glucose-to-potassium ratio: a predictor of poor functional outcomes in stroke patients receiving thrombolytic therapy
Background: The glucose-to-potassium ratio has shown promise as a biomarker in neurological disorders, but its prognostic value in acute ischemic stroke (AIS) after intravenous thrombolysis (IVT) continues to be uncertain. The study explores the relationship between admission GPR and 90-day functional outcomes in AIS patients undergoing IVT treatment.Methods: A retrospective analysis included 649 AIS patients undergoing IVT between May 2016 and December 2023. Baseline clinical, laboratory, and imaging data were analyzed. GPR was calculated from serum glucose and potassium levels at admission. A modified Rankin Scale score of 3 to 6 at 90 days was used to define poor functional outcomes. Logistic regression and restricted cubic splines assessed the GPR-outcome relationship, adjusting for confounders. Receiver operating characteristic (ROC) analysis evaluated GPR’s predictive value.Results: Among 649 patients, 174 (26.8%) had poor outcomes. Median GPR was significantly higher in these patients (2.14 vs. 1.88, p < 0.001). Higher GPR independently predicted negative consequences (OR, 1.821; 95% CI, 1.340–2.473, p < 0.001). Subgroup analysis indicated a stronger association in non-diabetic patients. ROC analysis demonstrated an area under the curve (AUC) of 0.631 (95% CI, 0.585–0.677, p < 0.001) for GPR in predicting poor functional outcomes.Conclusion: High GPR levels are independently linked to unfavorable 90-day functional outcomes in AIS patients who received IVT, suggesting its potential as a prognostic biomarker. Further studies are warranted to validate these findings.
- Open Access
- 1 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1519383
Pharmacogenetics polygenic response score predicts outcomes in aspirin-treated stroke patients
Background: Aspirin is a cornerstone medication for acute ischemic stroke (AIS), but its efficacy varies significantly among individuals. This study aimed to develop a pharmacogenetic polygenic response score (PgxRS) to predict the incidence of adverse outcomes in aspirin-treated AIS patients.Methods: We conducted a retrospective study involving 828 AIS patients who received aspirin therapy. Fifteen candidate single nucleotide variants (SNPs) in genes related to aspirin’s mechanism of action, transport, metabolism, and platelet function were genotyped. The association between SNPs and the risk of unfavorable prognosis (defined as modified Rankin Scale score >1 at 90 days) was assessed using logistic regression analysis. Multivariable models incorporating SNPs and clinical factors were developed to predict adverse outcomes.Results: The rs1045642GG genotype in the ABCB1 gene was significantly associated with a lower risk of unfavorable prognosis, while the rs1371097T allele in the P2Y1 gene was linked to a higher risk. A prediction model incorporating these two SNPs along with clinical variables demonstrated moderate diagnostic accuracy for predicting unfavorable prognosis (AUC = 0.78, 95% CI: 0.74–0.81).Conclusion: Our findings suggest that rs1045642 and rs1371097 genotypes contribute to variability in aspirin response among AIS patients. The developed PgxRS, incorporating these SNPs and clinical factors, can potentially aid in risk stratification and guide personalized antiplatelet therapy decisions. However, further validation in larger, diverse cohorts is warranted.
- 1 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1519383
Open AccessPharmacogenetics polygenic response score predicts outcomes in aspirin-treated stroke patients
Background: Aspirin is a cornerstone medication for acute ischemic stroke (AIS), but its efficacy varies significantly among individuals. This study aimed to develop a pharmacogenetic polygenic response score (PgxRS) to predict the incidence of adverse outcomes in aspirin-treated AIS patients.Methods: We conducted a retrospective study involving 828 AIS patients who received aspirin therapy. Fifteen candidate single nucleotide variants (SNPs) in genes related to aspirin’s mechanism of action, transport, metabolism, and platelet function were genotyped. The association between SNPs and the risk of unfavorable prognosis (defined as modified Rankin Scale score >1 at 90 days) was assessed using logistic regression analysis. Multivariable models incorporating SNPs and clinical factors were developed to predict adverse outcomes.Results: The rs1045642GG genotype in the ABCB1 gene was significantly associated with a lower risk of unfavorable prognosis, while the rs1371097T allele in the P2Y1 gene was linked to a higher risk. A prediction model incorporating these two SNPs along with clinical variables demonstrated moderate diagnostic accuracy for predicting unfavorable prognosis (AUC = 0.78, 95% CI: 0.74–0.81).Conclusion: Our findings suggest that rs1045642 and rs1371097 genotypes contribute to variability in aspirin response among AIS patients. The developed PgxRS, incorporating these SNPs and clinical factors, can potentially aid in risk stratification and guide personalized antiplatelet therapy decisions. However, further validation in larger, diverse cohorts is warranted.
- Open Access
- 28 January 2025
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 88 (4) , 273-282
A clinical-radiomics nomogram to predict early neurological deterioration in patients with stroke undergoing intravenous thrombolysis
Background: Anticipating early neurological deterioration in patients with ischemic stroke undergoing intravenous thrombolysis poses a considerable challenge in clinical practice. This study aimed to develop and validate a diffusion-weighted imaging (DWI)-based clinical-radiomics nomogram for predicting early neurological deterioration in patients with ischemic stroke without large vessel occlusion or hemorrhagic transformation undergoing intravenous thrombolysis. Methods: A total of 273 patients with stroke were randomly divided into training (n = 192) and validation (n = 81) cohorts at a ratio of 7:3. DWI images taken within 24 hours post-intravenous thrombolysis were used to extract radiological features. The t test, least absolute shrinkage, and selection operator algorithm were used for feature selection. These features were used to create a radiomics score (radscore) for each patient. Combined with the clinical features, a logistic regression model was used to select independent risk factors that were used to construct a clinical-radiomics nomogram. The performance of the nomogram was evaluated using the area under the curve (AUC), calibration, discrimination, and decision curve analysis. Results: A total of 1307 radiomics features were extracted from each patient’s data. A total of 310 radiomics features were found to be stable after being screened by intraclass correlation coefficients. Seven features were included in the construction of the radscore. The AUC of the clinical-radiomics nomogram was 0.89 (95% CI, 0.83-0.95) in the training cohort and 0.95 (95% CI, 0.90-0.99) in the validation cohort. The calibration curve and decision curve analysis indicated favorable calibration and net clinical benefits of the nomogram. Conclusion: A DWI-based clinical-radiomics nomogram can effectively predict early neurological deterioration in patients with ischemic stroke in the early phase after intravenous thrombolysis.
- 28 January 2025
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 88 (4) , 273-282
Open AccessA clinical-radiomics nomogram to predict early neurological deterioration in patients with stroke undergoing intravenous thrombolysis
Background: Anticipating early neurological deterioration in patients with ischemic stroke undergoing intravenous thrombolysis poses a considerable challenge in clinical practice. This study aimed to develop and validate a diffusion-weighted imaging (DWI)-based clinical-radiomics nomogram for predicting early neurological deterioration in patients with ischemic stroke without large vessel occlusion or hemorrhagic transformation undergoing intravenous thrombolysis. Methods: A total of 273 patients with stroke were randomly divided into training (n = 192) and validation (n = 81) cohorts at a ratio of 7:3. DWI images taken within 24 hours post-intravenous thrombolysis were used to extract radiological features. The t test, least absolute shrinkage, and selection operator algorithm were used for feature selection. These features were used to create a radiomics score (radscore) for each patient. Combined with the clinical features, a logistic regression model was used to select independent risk factors that were used to construct a clinical-radiomics nomogram. The performance of the nomogram was evaluated using the area under the curve (AUC), calibration, discrimination, and decision curve analysis. Results: A total of 1307 radiomics features were extracted from each patient’s data. A total of 310 radiomics features were found to be stable after being screened by intraclass correlation coefficients. Seven features were included in the construction of the radscore. The AUC of the clinical-radiomics nomogram was 0.89 (95% CI, 0.83-0.95) in the training cohort and 0.95 (95% CI, 0.90-0.99) in the validation cohort. The calibration curve and decision curve analysis indicated favorable calibration and net clinical benefits of the nomogram. Conclusion: A DWI-based clinical-radiomics nomogram can effectively predict early neurological deterioration in patients with ischemic stroke in the early phase after intravenous thrombolysis.
- Open Access
- 18 January 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 931405
Personalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: A prospective, randomized controlled trial
Background: Clopidogrel is frequently used in patients with ischemic stroke or transient ischemic attack (TIA), but its efficacy is hampered by inter-individual variability, due to genetic differences associated with clopidogrel metabolism. We conducted this randomized controlled trial to validate whether the personalized antiplatelet therapy based on clopidogrel pharmacogenomics and clinical characteristics leads to better clinical outcomes compared with standard treatment.Methods: Patients were randomly divided into the standard group or pharmacogenetic group, in which the pharmacogenetic group required the detection of the genotyping of CYP2C19*2, CYP2C19*3, and CYP2C19*17. Patients were followed up for 90 days for the primary efficacy endpoint of new stroke events, secondary efficacy endpoint of individual or composite outcomes of the new clinical vascular events, and the incidence of disability. The primary safety outcome was major bleeding.Results: A total of 650 patients underwent randomization, among which 325 were in the pharmacogenomics group while 325 were in the standard group. Our study found after a 90-day follow-up, the risk of stroke and composite vascular events in the pharmacogenomics group was lower than that in the standard group. The incidence of disability significantly decreased in the pharmacogenomics group. In addition, no statistically significant differences were observed in bleeding events between the two groups.Conclusion: The present study demonstrates that personalized antiplatelet therapy guided by clopidogrel pharmacogenomics and clinical characteristics can significantly improve the net clinical benefit of ischemic stroke or TIA patients during the 90-day treatment period without increasing bleeding risk.
- 18 January 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 931405
Open AccessPersonalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: A prospective, randomized controlled trial
Background: Clopidogrel is frequently used in patients with ischemic stroke or transient ischemic attack (TIA), but its efficacy is hampered by inter-individual variability, due to genetic differences associated with clopidogrel metabolism. We conducted this randomized controlled trial to validate whether the personalized antiplatelet therapy based on clopidogrel pharmacogenomics and clinical characteristics leads to better clinical outcomes compared with standard treatment.Methods: Patients were randomly divided into the standard group or pharmacogenetic group, in which the pharmacogenetic group required the detection of the genotyping of CYP2C19*2, CYP2C19*3, and CYP2C19*17. Patients were followed up for 90 days for the primary efficacy endpoint of new stroke events, secondary efficacy endpoint of individual or composite outcomes of the new clinical vascular events, and the incidence of disability. The primary safety outcome was major bleeding.Results: A total of 650 patients underwent randomization, among which 325 were in the pharmacogenomics group while 325 were in the standard group. Our study found after a 90-day follow-up, the risk of stroke and composite vascular events in the pharmacogenomics group was lower than that in the standard group. The incidence of disability significantly decreased in the pharmacogenomics group. In addition, no statistically significant differences were observed in bleeding events between the two groups.Conclusion: The present study demonstrates that personalized antiplatelet therapy guided by clopidogrel pharmacogenomics and clinical characteristics can significantly improve the net clinical benefit of ischemic stroke or TIA patients during the 90-day treatment period without increasing bleeding risk.
- 16 November 2022
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 107, 138-143
Elevated ApoB/ApoA-Ι ratio is associated with poor outcome in acute ischemic stroke
- 16 November 2022
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 107, 138-143
Elevated ApoB/ApoA-Ι ratio is associated with poor outcome in acute ischemic stroke